Literature DB >> 31631728

The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.

Daniel Filip1,2, Marek Mraz1,2.   

Abstract

MYC was found to be involved in many germinal center derived lymphomas, and more recently in the histological transformation of indolent mature B-cell malignancies, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) and mucosa-associated lymphoid tissue lymphoma (MALT) to aggressive diffuse large B-cell lymphoma (DLBCL). Pathological MYC activity gain in lymphomas is able to overcome its regulation by repressors, which leads to bypassing the affinity-based selection of B-cells. Arguably the MYC activity gain is the most constantly observed phenomenon (>70% of cases) in transformed FL/MALT/CLL (Richter's transformation) and co-occurs with specific aberrations such as the loss of p53, CDKN2A/B, or gain of BCL2/BCL6. Here we summarize recent progress in the understanding of MYC regulatory network in lymphoma B-cells and highlight its involvement in lymphomas' histological transformation by regulating cyclins, CDKs, p21, p27, BCL2, E2F, FOXP1, BCR signaling components, and non-coding microRNA (miRNA) genes such as miR-150, miR-29, miR-17-92, and miR-34a.

Entities:  

Keywords:  Lymphomas; MYC; indolent mature B-cell malignancies; microRNA; transformation

Mesh:

Substances:

Year:  2019        PMID: 31631728     DOI: 10.1080/10428194.2019.1675877

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations.

Authors:  Eva Ondroušková; Michaela Bohúnová; Kristýna Závacká; Patrik Čech; Petra Šmuhařová; Miroslav Boudný; Martina Oršulová; Anna Panovská; Lenka Radová; Michael Doubek; Karla Plevová; Marie Jarošová
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

2.  T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.

Authors:  Colin J Daniel; Carl Pelz; Xiaoyan Wang; Michael W Munks; Aaron Ko; Dhaarini Murugan; Sarah A Byers; Eleonora Juarez; Karyn L Taylor; Guang Fan; Lisa M Coussens; Jason M Link; Rosalie C Sears
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

Review 3.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 4.  LncRNAs in adaptive immunity: role in physiological and pathological conditions.

Authors:  Pedro Faria Zeni; Marek Mraz
Journal:  RNA Biol       Date:  2020-11-09       Impact factor: 4.652

Review 5.  Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.

Authors:  Benedetta Apollonio; Nikolaos Ioannou; Despoina Papazoglou; Alan G Ramsay
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 6.  "Double-Hit" Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes.

Authors:  Florence Nguyen-Khac
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 7.  O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.

Authors:  David E Spaner
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

8.  Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.

Authors:  Laura Ondrisova; Marek Mraz
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

Review 9.  The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.

Authors:  Pinelopi I Artemaki; Petros A Letsos; Ioanna C Zoupa; Katerina Katsaraki; Paraskevi Karousi; Sotirios G Papageorgiou; Vasiliki Pappa; Andreas Scorilas; Christos K Kontos
Journal:  Biomedicines       Date:  2021-03-25

Review 10.  The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.

Authors:  Gabriela Pavlasova; Marek Mraz
Journal:  Haematologica       Date:  2020-06       Impact factor: 11.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.